Literature DB >> 12601281

Is there a role for genetic testing in patients with melanoma?

Richard F Kefford1, Graham J Mann.   

Abstract

Autosomal dominant inheritance of mutations in the locus or the gene may confer a high risk of cutaneous melanoma development. The penetrance of mutations is influenced by UV exposure. Inherited variants in the melanocortin-1 receptor also confer increased risk of cutaneous melanoma. Features associated with increased genetic susceptibility to cutaneous melanoma include the presence of multiple affected first-degree relatives on one side of the family, multiple primary melanomas in the same individual, earlier age of onset, and the presence of multiple atypical nevi, but none of these factors reliably predicts for the presence of mutations. It is currently premature to offer predictive DNA testing for melanoma outside of defined research protocols. This is because of (1). the low likelihood of finding mutations in known melanoma susceptibility genes, even in more than 60% of melanoma-prone kindreds; (2). the broad confidence limits on current estimates of lifetime penetrance of mutations and the wide variation in this penetrance with locality; (3). a high "background" incidence of melanoma in non-mutation carriers in melanoma-prone families; (4). current uncertainties about the factors determining the functionality and phenotypic expression of the trait among carriers of these mutations (penetrance), even if found; and (5). the lack of proved efficacy of melanoma prevention and surveillance strategies, even for mutation carriers. Rather than singling out those deemed to be at high risk because of family history, all patients carrying risk factors for cutaneous melanoma should be subject to stringent programs of sun protection and skin surveillance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601281     DOI: 10.1097/00001622-200303000-00007

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  9 in total

1.  Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Samantha L Leaf; Wendy Kohlmann; Sancy A Leachman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-15       Impact factor: 4.254

2.  Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility.

Authors:  Nadine A Kasparian; Bettina Meiser; Phyllis N Butow; R F Soames Job; Graham J Mann
Journal:  J Genet Couns       Date:  2006-12       Impact factor: 2.537

3.  Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  J Genet Couns       Date:  2013-12-10       Impact factor: 2.537

4.  Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma.

Authors:  N A Kasparian; J K McLoone; B Meiser; P N Butow; J M Simpson; G J Mann
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

5.  "Melanoma: Questions and Answers." Development and evaluation of a psycho-educational resource for people with a history of melanoma.

Authors:  Nadine A Kasparian; Shab Mireskandari; Phyllis N Butow; Mbathio Dieng; Anne E Cust; Bettina Meiser; Kristine Barlow-Stewart; Scott Menzies; Graham J Mann
Journal:  Support Care Cancer       Date:  2016-07-27       Impact factor: 3.603

6.  Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.

Authors:  Barbara Peric; Petra Cerkovnik; Srdjan Novakovic; Janez Zgajnar; Nikola Besic; Marko Hocevar
Journal:  BMC Med Genet       Date:  2008-09-19       Impact factor: 2.103

7.  Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  Genet Med       Date:  2014-04-24       Impact factor: 8.822

Review 8.  Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants.

Authors:  Kristen Pauley; Ambreen Khan; Wendy Kohlmann; Joanne Jeter
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

9.  Management of melanoma families.

Authors:  Wilma Bergman; Nelleke A Gruis
Journal:  Cancers (Basel)       Date:  2010-04-16       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.